NasdaqHealth CareHealth Care ServicesS&P SmallCap 600
$34.84
+0.47 (+1.37%)
Close of Nov 06, 2026 · end-of-day data
PGNY 8-K filings in 2026
Every material Form 8-K Progyny filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Progyny reported record third-quarter 2026 revenue of $341.3 million, up 8.9%, and net income of $26.3 million, or $0.32 per diluted share, versus $13.9 million, or $0.15, a year earlier. The company raised the midpoint of its full-year 2026 guidance ranges, which signals that management expects stronger results for the year.
Q3 2026 net income was $26.3 million, or $0.32 per diluted share, versus $13.9 million, or $0.15, in Q3 2025.
Q3 2026 Adjusted EBITDA was $58.4 million, up 6.3%, with a margin of 17.1% versus 17.5% a year earlier.
Full-year 2026 revenue is projected at $1.365 billion to $1.385 billion, and net income at $107.0 million to $110.6 million.
Nearly 11 million shares were repurchased in 2026 so far, with approximately $51 million remaining under the current authorization.
Progyny reported second-quarter 2026 revenue of $350.5 million, up 5.3% from $332.9 million, and net income of $28.1 million, or $0.34 per diluted share, versus $0.19 a year earlier. The company also issued third-quarter and full-year 2026 guidance and said it has repurchased 2 million shares under its May 2026 program, with about $142.5 million remaining under that authorization.
Revenue was $350.5 million, up 5.3%; fertility benefit services revenue rose 7.6% to $230.2 million.
Diluted EPS was $0.34 versus $0.19; adjusted EPS was $0.55 versus $0.48.
Q3 2026 revenue is projected at $335.0 million to $345.0 million; full-year 2026 revenue at $1.360 billion to $1.385 billion.
Operating cash flow was $50.4 million versus $55.5 million a year earlier; the company had no debt as of June 30, 2026.
Progyny reported first quarter 2026 revenue of $328.5 million, up 1.4%, and net income of $24.2 million, or $0.29 per diluted share, compared with $15.1 million, or $0.17, a year earlier. Adjusted EBITDA fell 2.1% to $56.6 million as the company made planned platform investments, and the company issued full-year 2026 guidance with revenue of $1.365 billion to $1.405 billion.
Revenue was $328.5 million, up 1.4% from $324.0 million; excluding $31.3 million from a large client in the prior-year period, revenue rose 12.2%.
Net income was $24.2 million, or $0.29 per diluted share, versus $15.1 million, or $0.17, in Q1 2025; Adjusted EBITDA was $56.6 million, down 2.1%.
The November 2025 share repurchase program ($200 million authorization) is complete, with 8.8 million shares bought; the board expects a decision on a new program around the end of May.
Full-year 2026 guidance: revenue of $1.365 billion to $1.405 billion, net income of $103.7 million to $112.3 million, and Adjusted EBITDA of $232.0 million to $244.0 million.
Progyny reported fourth-quarter 2025 revenue of $318.4 million, up 6.7%, and full-year revenue of $1,288.7 million, up 10%. Full-year diluted earnings per share rose to $0.65 from $0.57, and the company issued 2026 guidance for revenue of $1.355 billion to $1.405 billion and net income of $95.4 million to $106.1 million. The Q1 2026 revenue outlook of (1.6)% to 2.5% growth signals modest near-term growth.
Q4 2025 revenue was $318.4 million, up from $298.4 million; a large client that did not renew contributed $35.9 million in Q4 2024 and none in Q4 2025.
Full-year 2025 net income was $58.5 million, or $0.65 per diluted share, versus $54.3 million, or $0.57, in 2024.
2026 outlook: revenue of $1.355 billion to $1.405 billion and net income of $95.4 million to $106.1 million.
Q1 2026 revenue is projected at $319.0 million to $332.0 million, growth of (1.6)% to 2.5%.
Progyny said on January 12, 2026 that its fourth-quarter 2025 revenue, net income and Adjusted EBITDA are now expected to be slightly above the ranges it gave in November 2025. The company said this excludes any non-cash impacts to net income tied to the previously announced departure of president Michael Sturmer, and that member engagement paced favorably during the quarter. Shareholders get an upward revision to recent guidance, though the filing does not give specific dollar figures.
Fourth-quarter 2025 revenue, net income and Adjusted EBITDA are expected to be slightly above the November 2025 guidance ranges.
The outlook excludes any non-cash impacts to net income from the departure of president Michael Sturmer.
CEO Pete Anevski cited member engagement that paced favorably versus the November guidance.
Management will discuss the updated expectations at the JP Morgan Healthcare Conference on Tuesday, January 13, 2026, at 10:30 a.m. Eastern Time.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Progyny filing is on SEC EDGAR ↗. 8-K briefs of other companies →